Stay updated on Nivolumab for IDH Mutant Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.

Latest updates to the Nivolumab for IDH Mutant Gliomas Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.2%
- Check14 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as detailed information on various proteins and antibodies relevant to pathological conditions. Notably, previous references to specific genetic diseases and certain antineoplastic agents have been removed.SummaryDifference2%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
- Check50 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and includes a mention of HHS Vulnerability Disclosure.SummaryDifference0.2%
Stay in the know with updates to Nivolumab for IDH Mutant Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.